European Stroke Organization

Link to this page

European Stroke Organization

Authors

Publications

Cognitive impairment in patients with cerebrovascular disease: A white paper from the ESO Dementia Committee

Verdelho, Ana; Wardlaw, Joanna; Pavlović, Aleksandra; Pantoni, Leonardo; Godefroy, Olivier; Duering, Marco; Charidimou, Andreas; Chabriat, Hugues; Biessels, Geert Jan

(Sage Publications Ltd, London, 2021)

TY  - JOUR
AU  - Verdelho, Ana
AU  - Wardlaw, Joanna
AU  - Pavlović, Aleksandra
AU  - Pantoni, Leonardo
AU  - Godefroy, Olivier
AU  - Duering, Marco
AU  - Charidimou, Andreas
AU  - Chabriat, Hugues
AU  - Biessels, Geert Jan
PY  - 2021
UR  - http://rfasper.fasper.bg.ac.rs/handle/123456789/1324
AB  - Purpose Many daily-life clinical decisions in patients with cerebrovascular disease and cognitive impairment are complex. Evidence-based information sustaining these decisions is frequently lacking. The aim of this paper is to propose a practical clinical approach to cognitive impairments in patients with known cerebrovascular disease. Methods The document was produced by the Dementia Committee of the European Stroke Organisation (ESO), based on evidence from the literature where available and on the clinical experience of the Committee members. This paper was endorsed by the ESO. Findings Many patients with stroke or other cerebrovascular disease have cognitive impairment, but this is often not recognized. With improvement in acute stroke care, and with the ageing of populations, it is expected that more stroke survivors and more patients with cerebrovascular disease will need adequate management of cognitive impairment of vascular etiology. This document was conceived for the use of strokologists and for those clinicians involved in cerebrovascular disease, with specific and practical hints concerning diagnostic tools, cognitive impairment management and decision on some therapeutic options. Discussion and conclusions: It is essential to consider a possible cognitive deterioration in every patient who experiences a stroke. Neuropsychological evaluation should be adapted to the clinical status. Brain imaging is the most informative biomarker concerning prognosis. Treatment should always include adequate secondary prevention.
PB  - Sage Publications Ltd, London
T2  - European Stroke Journal
T1  - Cognitive impairment in patients with cerebrovascular disease: A white paper from the ESO Dementia Committee
EP  - 17
IS  - 1
SP  - 5
VL  - 6
DO  - 10.1177/23969873211000258
ER  - 
@article{
author = "Verdelho, Ana and Wardlaw, Joanna and Pavlović, Aleksandra and Pantoni, Leonardo and Godefroy, Olivier and Duering, Marco and Charidimou, Andreas and Chabriat, Hugues and Biessels, Geert Jan",
year = "2021",
abstract = "Purpose Many daily-life clinical decisions in patients with cerebrovascular disease and cognitive impairment are complex. Evidence-based information sustaining these decisions is frequently lacking. The aim of this paper is to propose a practical clinical approach to cognitive impairments in patients with known cerebrovascular disease. Methods The document was produced by the Dementia Committee of the European Stroke Organisation (ESO), based on evidence from the literature where available and on the clinical experience of the Committee members. This paper was endorsed by the ESO. Findings Many patients with stroke or other cerebrovascular disease have cognitive impairment, but this is often not recognized. With improvement in acute stroke care, and with the ageing of populations, it is expected that more stroke survivors and more patients with cerebrovascular disease will need adequate management of cognitive impairment of vascular etiology. This document was conceived for the use of strokologists and for those clinicians involved in cerebrovascular disease, with specific and practical hints concerning diagnostic tools, cognitive impairment management and decision on some therapeutic options. Discussion and conclusions: It is essential to consider a possible cognitive deterioration in every patient who experiences a stroke. Neuropsychological evaluation should be adapted to the clinical status. Brain imaging is the most informative biomarker concerning prognosis. Treatment should always include adequate secondary prevention.",
publisher = "Sage Publications Ltd, London",
journal = "European Stroke Journal",
title = "Cognitive impairment in patients with cerebrovascular disease: A white paper from the ESO Dementia Committee",
pages = "17-5",
number = "1",
volume = "6",
doi = "10.1177/23969873211000258"
}
Verdelho, A., Wardlaw, J., Pavlović, A., Pantoni, L., Godefroy, O., Duering, M., Charidimou, A., Chabriat, H.,& Biessels, G. J.. (2021). Cognitive impairment in patients with cerebrovascular disease: A white paper from the ESO Dementia Committee. in European Stroke Journal
Sage Publications Ltd, London., 6(1), 5-17.
https://doi.org/10.1177/23969873211000258
Verdelho A, Wardlaw J, Pavlović A, Pantoni L, Godefroy O, Duering M, Charidimou A, Chabriat H, Biessels GJ. Cognitive impairment in patients with cerebrovascular disease: A white paper from the ESO Dementia Committee. in European Stroke Journal. 2021;6(1):5-17.
doi:10.1177/23969873211000258 .
Verdelho, Ana, Wardlaw, Joanna, Pavlović, Aleksandra, Pantoni, Leonardo, Godefroy, Olivier, Duering, Marco, Charidimou, Andreas, Chabriat, Hugues, Biessels, Geert Jan, "Cognitive impairment in patients with cerebrovascular disease: A white paper from the ESO Dementia Committee" in European Stroke Journal, 6, no. 1 (2021):5-17,
https://doi.org/10.1177/23969873211000258 . .
32
42
10
33